Physicians' Academy for Cardiovascular Education

How to implement the newest heart failiure therapies? - A case-based approach

Find here videos of the 3rd Groningen Heart Failure symposium entitled: How to implement the newest heart failiure therapies? - A case-based approach.

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD
Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.

Hyperkalemia drives suboptimal use of RAASi therapy, which is associated with increased CV risk in HF patients. Prof. Zannad presents trial results with the new potassium binders ZS-9 and patiromer.

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD
Niels Grote Beverborg talks about multiple aspects of iron deficiency without anemia in HF, including outcomes, mechanisms, diagnosis, etiology and treatment options.

Niels Grote Beverborg talks about multiple aspects of iron deficiency without anemia in HF, including outcomes, mechanisms, diagnosis, etiology and treatment options.

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD
Which characteristics increase clinical suspicion for amyloidosis, and how should ATTR-cardiomyopathy, a type of amyloidosis, be diagnosed and treated?

Which characteristics increase clinical suspicion for amyloidosis, and how should ATTR-cardiomyopathy, a type of amyloidosis, be diagnosed and treated?

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD
Two dilemmas in use of sacubitril/valsartan for heart failure patients are discussed in this presentation: Should sacubitril/valsartan be used in HFpEF patients and as initial treatment in HFrEF patients?

Two dilemmas in use of sacubitril/valsartan for heart failure patients are discussed in this presentation: Should sacubitril/valsartan be used in HFpEF patients and as initial treatment in HFrEF patients?

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD
The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. The presentations in this series may help in decision-making in a personalized, case-based approach.

The co-chairs introduce the topic of this symposium by explaining that many novel therapies for HFrEF have resulted in difficulties in decision-making for management of these patients. The presentations in this series may help in decision-making in a personalized, case-based approach.

How to implement the newest heart failiure therapies? - A case-based approach